800 related articles for article (PubMed ID: 16275807)
1. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
Lane HY; Lin CH; Huang YJ; Liao CH; Chang YC; Tsai GE
Int J Neuropsychopharmacol; 2010 May; 13(4):451-60. PubMed ID: 19887019
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
4. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
[TBL] [Abstract][Full Text] [Related]
5. D-alanine added to antipsychotics for the treatment of schizophrenia.
Tsai GE; Yang P; Chang YC; Chong MY
Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544
[TBL] [Abstract][Full Text] [Related]
6. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Tsai G; Lane HY; Yang P; Chong MY; Lange N
Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
[TBL] [Abstract][Full Text] [Related]
7. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
8. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Heresco-Levy U; Javitt DC; Ebstein R; Vass A; Lichtenberg P; Bar G; Catinari S; Ermilov M
Biol Psychiatry; 2005 Mar; 57(6):577-85. PubMed ID: 15780844
[TBL] [Abstract][Full Text] [Related]
9. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
10. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
11. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
Singh SP; Singh V
CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
[TBL] [Abstract][Full Text] [Related]
14. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
Ghajar A; Gholamian F; Tabatabei-Motlagh M; Afarideh M; Rezaei F; Ghazizadeh-Hashemi M; Akhondzadeh S
Hum Psychopharmacol; 2018 Jul; 33(4):e2662. PubMed ID: 29901250
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
[TBL] [Abstract][Full Text] [Related]
16. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
17. ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan.
Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang LJ; Lee IH; Wang TY; Chen KC; Yang YK; Hong JS; Lu RB
J Psychiatr Res; 2015 Oct; 69():50-6. PubMed ID: 26343594
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY
World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576
[TBL] [Abstract][Full Text] [Related]
19. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
20. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
Chan HY; Lin AS; Chen KP; Cheng JS; Chen YY; Tsai CJ
J Clin Psychopharmacol; 2013 Dec; 33(6):747-52. PubMed ID: 24100785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
